Protection was strongest in the first month, when vulnerability is greatest.
Each winter, respiratory syncytial virus quietly claims tens of thousands of young lives before immune systems have had time to mature. A real-world study from western Pennsylvania now offers measured reassurance: when pregnant women receive the RSV prefusion F vaccine, the antibodies they generate cross the placenta and appear to shield their newborns through the most dangerous early weeks, reducing hospitalization risk by roughly two-thirds. The finding, drawn from two consecutive RSV seasons, suggests that protecting a child can begin before the child draws its first breath.
- RSV hospitalizes 3.6 million children under five every year and kills around 100,000 of them — half of those hospitalizations strike infants younger than six months, before their immune systems can mount a meaningful defense.
- Among 274 hospitalized infants studied across two RSV seasons, vaccinated mothers' babies were dramatically underrepresented in the RSV-positive group — 37% of RSV-negative infants had vaccinated mothers, compared to only 13% of those who contracted the virus.
- The maternal vaccine, approved by the FDA in 2023 for use at 32–36 weeks of pregnancy, achieved 68% effectiveness against hospitalization in infants under 90 days and 74% in the critical first month of life.
- The study's real-world design — including preterm infants and multiple-birth pregnancies — strengthens its relevance, though a single regional health system and small sample size leave wide confidence intervals and limit how broadly the results can be applied.
- Larger, multi-region studies are now needed to confirm how long maternal antibody protection lasts and whether adjusting the vaccination window could push effectiveness even higher.
A study of 274 hospitalized infants in western Pennsylvania has found that newborns born to vaccinated mothers face substantially lower odds of severe RSV infection. The FDA-approved prefusion F vaccine, given to pregnant women between 32 and 36 weeks of gestation, showed 68% effectiveness against RSV-related hospitalization in infants up to 90 days old — and 74% effectiveness in the first month of life, when vulnerability is greatest.
RSV remains one of the most serious threats to infant health worldwide, causing roughly 3.6 million hospitalizations and 100,000 deaths annually among children under five. In the United States, infants under three months are hospitalized at a rate of 24 per 1,000 — and half of all RSV hospitalizations occur before six months of age. The vaccine works by prompting the mother's immune system to produce antibodies that cross the placenta, giving the newborn passive protection during those fragile early weeks.
Researchers compared two RSV seasons from 2023 to 2025, tracking infants born to vaccinated and unvaccinated mothers. Of the 274 hospitalized infants tested for RSV, 83 tested positive. The contrast was stark: vaccinated mothers accounted for 37% of RSV-negative cases but only 13% of RSV-positive ones. Among infected infants, 87% developed lower respiratory tract disease, 34% required intensive care, and 68% needed oxygen or respiratory support — far higher rates than among those who tested negative.
The study's real-world design is one of its strengths, capturing preterm infants and multiple pregnancies that clinical trials often exclude. Investigators used a narrower vaccination window than the original pivotal trial yet achieved comparable protection. Still, the research comes from a single regional health system, and the relatively small sample produced wide confidence intervals. The study was supported by Pfizer, though the company did not participate in data collection or analysis.
Taken together, the findings reinforce maternal RSV vaccination as a practical strategy for protecting newborns through their most vulnerable months — and add real-world weight to the clinical trial evidence that led to the vaccine's approval.
A study of 274 hospitalized infants in western Pennsylvania has found that when pregnant women receive the RSV prefusion F vaccine, their newborns face substantially lower odds of severe respiratory syncytial virus infection requiring hospitalization. The vaccine, approved by the FDA in 2023 for use between 32 and 36 weeks of pregnancy, showed 68% effectiveness against RSV-related hospitalization in infants up to 90 days old—and even stronger protection of 74% during the first month of life, when newborns are most vulnerable.
RSV remains a formidable threat to infants worldwide. The virus causes roughly 3.6 million hospitalizations annually among children under five, with about 100,000 deaths. In the United States, the hospitalization rate for RSV in infants under three months runs to 24 per 1,000 babies. Half of all RSV hospitalizations occur in infants younger than six months, a window when the immune system is still developing and the disease can turn severe quickly. The prefusion F vaccine works by stimulating the mother's immune system to produce antibodies that cross the placenta and protect the newborn in those critical early weeks.
The research team examined two RSV seasons spanning 2023 to 2025, comparing infants born to vaccinated mothers against those born to unvaccinated mothers. Of the 274 infants hospitalized with acute respiratory illness and tested for RSV, 83 tested positive. The vaccinated group showed a striking difference: 37% of infants without RSV had been born to vaccinated mothers, while only 13% of those who contracted RSV came from vaccinated pregnancies. Among the RSV-positive infants, 87% developed lower respiratory tract disease, 34% required intensive care, and 68% needed oxygen or respiratory support. By contrast, among those who tested negative for RSV, only 45% had lower respiratory tract involvement, 17% needed ICU care, and 21% required oxygen support.
The study's strength lies in its real-world design. Unlike controlled clinical trials, this research examined actual vaccination patterns and outcomes in a working hospital system, including preterm infants and those born to mothers with multiple pregnancies—populations that reflect the true diversity of births. The investigators also imposed a narrower vaccination window than the original clinical trial had used, yet still achieved comparable protection. The confidence intervals were wide, reflecting the relatively small sample size, but the point estimates aligned closely with the efficacy data from the pivotal trial that led to FDA approval.
The findings come with important caveats. The study involved only a single health system in one region, limiting generalizability. The observational design means researchers cannot definitively prove causation, though the study was structured to minimize confounding bias. The small sample size produced wide confidence intervals, particularly when researchers examined subgroups. Investigators noted that additional studies across different regions and larger populations are needed to confirm how long protection lasts and whether earlier vaccination—allowing more time for antibody development—might yield even stronger results.
Pfizer, the vaccine manufacturer, supported the research through a collaboration with the University of Pittsburgh, and several authors reported financial ties to the company. The company reviewed and approved the manuscript but did not participate in data collection, analysis, or the decision to publish.
The study adds to a growing body of evidence that maternal RSV vaccination represents a practical tool for protecting newborns during their most fragile months. Current guidelines recommend vaccination between 32 and 36 weeks and 6 days of gestation, a window that captures most pregnancies while allowing sufficient time for antibody transfer before birth. The findings suggest this strategy may prevent a meaningful share of the severe RSV hospitalizations that continue to burden families and hospitals each winter.
Citações Notáveis
The point estimate was highest during the first month of life, although confidence intervals were wide, and this is also the period of greatest vulnerability.— Study authors
A Conversa do Hearth Outra perspectiva sobre a história
Why does the first month of life matter so much for RSV protection?
That's when infants are most defenseless. Their own immune systems haven't fully developed, and maternal antibodies are at their highest concentration. After that first month, those borrowed antibodies start to fade, and the baby's own immune response is still ramping up. It's a narrow window of maximum vulnerability.
The study is small and from one hospital system. Does that undermine the findings?
It limits what we can claim, but it doesn't invalidate what they found. Real-world data from an actual hospital is valuable precisely because it shows what happens outside a controlled trial. The confidence intervals are wide, yes—that's honest about the uncertainty. But the point estimate of 68% protection matches what the clinical trial showed, which is reassuring.
What about the mothers who weren't vaccinated? Were they choosing not to, or did they miss the window?
The study doesn't tell us that. It's observational, so we see the outcome but not the reasoning. Some may have declined, some may have delivered early, some may have simply not been offered it. That's one reason larger studies across different regions would help—you'd see vaccination patterns and barriers more clearly.
If the vaccine works, why do we need more studies?
Because this one is small, from one place, and observational. We don't know yet how long protection lasts—does it fade after six months? A year? We also don't know if vaccinating earlier in pregnancy might work better. And we need to see if these results hold up in different populations, different hospitals, different regions. One study, even a good one, is a beginning, not an ending.
What happens to the babies born to unvaccinated mothers?
Some get RSV, some don't—it depends on exposure. But among those who do get infected, the data here shows they're more likely to need ICU care and oxygen support. That's the gap the vaccine is meant to close. Without it, you're relying on luck and on keeping the baby isolated, which isn't realistic.